Literature DB >> 12235249

5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat.

Amber Russell1, Amy Banes, Hilary Berlin, Gregory D Fink, Stephanie W Watts.   

Abstract

Arterial hyperresponsiveness to serotonin (5-hydroxytryptamine, 5-HT) is observed in experimental models and human forms of hypertension. Presently, we test the hypothesis that the 5-HT(2B) receptor is up-regulated and necessary for maintaining elevated blood pressure in a rat made hypertensive by the nitric-oxide synthase inhibitor N(omega)-nitro-L-arginine (LNNA; 0.5 g/l). After 2 weeks of treatment, thoracic aorta were removed from LNNA hypertensive (systolic blood pressure = 189 +/- 5 mm Hg) and sham normotensive rats (121 +/- 1 mm Hg), denuded, and mounted into isolated tissue baths for measurement of isometric contraction. In sham tissues, 5-HT-induced contraction was mediated by the 5-HT(2A) receptor as evidence by a parallel rightward shift in response to 5-HT by the 5-HT(2A/2C) receptor antagonist ketanserin (10 nM) and lack of shift by the 5-HT(2B) receptor antagonist 6-methyl-1,2,3,4-tetrahydro-1-[3,4-dimethoxyphenyl)methyl]-9H-pyrido[3,4-b]indole hydrochloride (LY272015) (10 nM). In contrast, LY272015 produced a 4-fold rightward shift to 5-HT in aorta from LNNA hypertensive rats, and blockade by ketanserin did not occur at low concentrations of 5-HT. Maximal contraction to the 5-HT(2B) receptor agonist 1-[5-(2-thienylmethoxy)-1H-3-indolyl]propan-2-amine hydrochloride was significantly greater in LNNA hypertensive rats (percentage of phenylephrine contraction in sham = 7 +/- 4, and in LNNA = 61 +/- 7%). 5-HT(2B) receptor protein was present in aortic homogenates from sham and LNNA rats, but the density of 5-HT(2B) receptor protein in LNNA homogenates was 300% that in sham. Importantly, the 5-HT(2B) receptor antagonist LY272015 reduced blood pressure of the LNNA hypertensive but not the sham normotensive rats. Thus, these data suggest that the up-regulated 5-HT(2B) receptor in the LNNA hypertensive rats is physiologically activated to maintain elevated blood pressure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235249     DOI: 10.1124/jpet.102.037390

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

3.  Serotonin receptors in rat jugular vein: presence and involvement in the contraction.

Authors:  A Elizabeth Linder; Geri L Gaskell; Theodora Szasz; Janice M Thompson; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2010-04-08       Impact factor: 4.030

Review 4.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

5.  5-HT is a potent relaxant in rat superior mesenteric veins.

Authors:  Stephanie W Watts; Emma S Darios; Bridget M Seitz; Janice M Thompson
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

6.  5HT(2A) and 5HT(2B) receptors contribute to serotonin-induced vascular dysfunction in diabetes.

Authors:  Peter M Nelson; Jeremy S Harrod; Kathryn G Lamping
Journal:  Exp Diabetes Res       Date:  2012-12-30

7.  Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension.

Authors:  Amy K L Banes; Stephanie W Watts
Journal:  BMC Pharmacol       Date:  2003-09-15

8.  Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.

Authors:  Yahan Liu; Zhipeng Wang; Jing Li; Yiqian Ban; Guangmei Mao; Man Zhang; Mo Wang; Yan Liu; Beilei Zhao; Qiang Shen; Qingbo Xu; Nanping Wang
Journal:  J Am Heart Assoc       Date:  2018-01-30       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.